Ovid Therapeutics
OVID
45 hedge funds and large institutions have $81.8M invested in Ovid Therapeutics in 2017 Q2 according to their latest regulatory filings, with 45 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
32.49% more ownership
Funds ownership: 0% → 32.49% (+32%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.7M |
| 2 |
BlackRock
New York
|
+$14.6M |
| 3 |
Jennison Associates
New York
|
+$8.49M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$7M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$5.86M |
Top Sellers
OVID Hedge Fund Activity: Q2 2017 in Review
45 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q2 2017, worth a combined $81.8M.
Buyers outnumbered sellers: 45 funds opened new OVID positions and 0 closed out — a net gain of 45 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $23.7M.
- 45 institutional investors held Ovid Therapeutics (OVID) as of Q2 2017, up from 0 in Q1 2017.
- Funds reported $81.8M of Ovid Therapeutics stock for Q2 2017.
- 45 funds opened new Ovid Therapeutics positions in Q2 2017 and 0 closed out, a net change of +45 holders.
- The largest Ovid Therapeutics buyer in Q2 2017 was Fidelity Investments, an estimated $23.7M added.
Based on aggregated 13F filings for Q2 2017.